Tofacitinib for Immune Skin Conditions in Down Syndrome

 

ID# NCT04246372

Recruitment Status:  recruiting as of August 2020.

 

Estimated Completion Date: August 2024

 

Sponsors and Collaborators: University of Colorado, Denver and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Information provided by (Responsible Party): University of Colorado, Denver

Brief Summary: People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is safe and could improve associated skin conditions.

The study evaluates the safety and efficacy treatment with Tofacitinib, an FDA-approved drug known to block IFN signaling, in adults with DS and an autoimmune and/or autoinflammatory skin condition. Investigators will also measure the impact of interferon inhibition on a variety of molecular markers, as well as the cognitive abilities and quality of life of participants.

Please link complete details: https://clinicaltrials.gov/ct2/show/NCT04246372

Location: Aurora, Colorado

Contact: Angela Rachubinski, PhD 303-724-7366, DSresearch@ucdenver.edu  

Belinda Enriquez Estrada, MS,   303-724-0491 DSresearch@ucdenver.edu

Location: Aarhus, Denmark

 

Contact: Kasper F Hjuler, MD PhD +4523882479 kasped@rm.dk or Louise F Møller louisras@rm.dk

Get Updates

Affiliated With

© 2020 by HS Connect   |  HSConnect.org@gmail.com  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579